UCB : Financial Reporting Document

This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, you are cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving conflicts, wars, pandemics, as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation or duty to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

Proprietary and Confidential Property of UCB

In the U.S.

BIMZLEX® (bimekizumab-bkzx) is approved for the treatment of

In the EU

Approved indications for BIMZELX ®▼ (bimekizumab) are:

moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.1

Plaque

Psoriasis

Psoriatic

Arthritis

Axial Spondyloarthritis

Bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.2

Bimekizumab, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).2

Bimekizumab is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP), and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidalanti-inflammatory drugs (NSAIDs), and for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.2

Proprietary and Confidential Property of UCB

Introduction

Emmanuel Caeymaex

Executive Vice President

Immunology Solutions & Head of U.S.

Proprietary and Confidential Property of UCB

Antje Witte

Head of Investor Relations, UCB

Emmanuel Caeymaex

Executive Vice President

Immunology Solutions & Head of U.S.

Agenda

Dr. Andrew Blauvelt

Blauvelt Consulting, LLC

Lake Oswego, OR, USA

Emmanuel Caeymaex

Executive Vice President

Immunology Solutions & Head of U.S.

WELCOME

INTRODUCTION

BIMZELX®

Four-Year Data in Moderate to Severe Plaque Psoriasis

SUMMARY

Proprietary and Confidential Property of UCB

IL-17 plays a pivotal role in the pathogenesis of immune-mediated inflammatory diseases

Innate immunity driven pathology5

Innate lymphocytes5 IL-175

Adaptive immunity driven pathology1

and Confidential Property of UCB

IL-235

Adaptive IL-175 lymphocytes5

Proprietary

IL-17 production by innate lymphocytes

can be independent of IL-236,7

†U.S. prevalence.

References: 1. National Psoriasis Foundation. Statistics. Available at: https://www.psoriasis.org/content/statistics. Last accessed: March 2024; 2. Gladman DD, et al. Ann Rheum Dis. 2005; 64 (Suppl 2): ii14-7; 3. Reveille JD. AM J Med Sci. 2013; 345(6):431-36. 4. Calao M et al. PLoS ONE. 2018;13(7):e0200683. 5. Tsukazaki H, Kaito T. Int J Mol Sci. 2020;21(17):6401. 6. Cole S et al. Front Immunol. 2020;11:585134. 7. Łukasik Z, et al. Rheumatology (Oxford). 2021;60(Suppl 4):iv16-iv2

GL-BK-2400026| Date of preparation: March 2024

IL-17F/F5

IL-17A/F5

IL-17A/A5

7

Patients with moderate to severe plaque psoriasis place a high value on treatment which provides*1

• Clear skin
• Sustained response
• Rapid onset of action

The most frequently reported treatment-emergent adverse event in bimekizumab-treated patients were nasopharyngitis, oral candidiasis, and upper respiratory tract infection*2,3

Proprietary and Confidential Property of UCB

PASI 100 with bimekizumab in patients with an inadequate response to secukinumab, ustekinumab or adalimumab PASI 90 (post hoc analyses)

Proportion of patients achieving PASI100 (%)

Proprietary and Confidential Property of UCB

Dr. Andrew Blauvelt

Blauvelt Consulting, LLC Lake Oswego, OR, USA

BIMZELX®

Four-Year Data in Moderate to Severe Plaque Psoriasis

Proprietary and Confidential Property of UCB